When asked at the Influenza Congress about the goals of Replikins Ltd., Dr. Bogoch replied: "Current biological vaccine technologies for emergent diseases are expected to provide, albeit 'too little and too late', approximately 125 million vaccine doses for people worldwide this fall (Klaus Stohr, Influenza Congress USA, Washington, DC, Nov. 19-20, 2009). Replikins synthetic vaccines are targeting emergent diseases in the unserved global population of over six billion people, and selected animal populations, and FluForecast(R) can give advance warning of outbreaks.
"The company has announced the formation of WorldVaccines(TM) Ltd to test and distribute these new Replikins technologies, and invites all interested public health, pharmaceutical, financial, and other institutions to join it in testing and distributing FluForecast(R) and Replikins' synthetic vaccines against emerging diseases."
Contact: Samuel Bogoch, MD, PhD, (646) 320-5910, email@example.com
Replikins are a new group of genomic peptide structures in viruses, other infectious disease agents, and cancer cells, which are associated with rapid replication (refs). Two genes have been isolated in silico in viruses and relate to infectivity and lethality respectively. The increase in Replikin concentration (Replikin Count=Number of Replikins per 100 amino acids) in the virus Infectivity Gene precedes an increase in clinical infectivity and spread; and an increase in the virus Lethality Gene precedes an increase in lethality clinically. The characteristic high infectivity and low lethality found in counting the Replikins in these two genes in the H1N1 strain correspond to what is observed clinically, that is, high infectivity and low lethality. In contrast, i
|Copyright©2009 PR Newswire.|
All rights reserved